Clinical Perspective Maternal| Volume 2, ISSUE 4, 100177, November 2020

Download started.


Early lessons from maternal mortality review committees on drug-related deaths—time for obstetrical providers to take the lead in addressing addiction

      The problem: In the United States, maternal mortality review committees are providing compelling data that drug-related deaths are emerging as a leading cause of pregnancy-associated death (death during pregnancy or up to a year postpartum). Recommendations from the maternal mortality review committees consistently highlight screening all pregnant and postpartum women for drug use and improving access to evidence-based substance use disorder and mental health treatment. Unfortunately, many providers lack the confidence, skills, and necessary resources to screen for substance use, provide basic behavioral health services, or facilitate referral to high-quality services in their clinical settings. Our profession’s collective lack of response to a leading cause of maternal death represents a missed opportunity for potentially life-saving interventions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology MFM
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Haight S.C.
        • Ko J.Y.
        • Tong V.T.
        • Bohm M.K.
        • Callaghan W.M.
        Opioid use disorder documented at delivery hospitalization - United States, 1999-2014.
        MMWR Morb Mortal Wkly Rep. 2018; 67: 845-849
        • Centers for Disease Control and Prevention
        2018 annual surveillance report of drug-related risks and outcomes: United States.
        (Available at:)
        • St Pierre A.
        • Zaharatos J.
        • Goodman D.
        • Callaghan W.M.
        Challenges and opportunities in identifying, reviewing, and preventing maternal deaths.
        Obstet Gynecol. 2018; 131: 138-142
      1. Review to Action. Definitions.
        (Available at:)
        Date accessed: February 13, 2020
        • Centers for Disease Control and Prevention
        Pregnancy Mortality Surveillance System.
        (Available at:)
        • Gemmill A.
        • Kiang M.V.
        • Alexander M.J.
        Trends in pregnancy-associated mortality involving opioids in the United States, 2007-2016.
        Am J Obstet Gynecol. 2019; 220: 115-116
        • Baeva S.
        • Archer N.P.
        • Ruggiero K.
        • et al.
        Maternal mortality in Texas.
        Am J Perinatol. 2017; 34: 614-620
        • Davis N.L.
        • Smoots A.N.
        • Goodman D.A.
        Pregnancy-related deaths: data from 14 U.S. maternal mortality review committees, 2008-2017.
        Centers for Disease Control and Prevention, United States Department of Health and Human Services, Atlanta, GA2019
        • Smid M.C.
        • Maeda J.
        • Stone N.
        • et al.
        Standardized criteria for review of perinatal suicides and accidental drug-related deaths.
        Obstet Gynecol. 2020;
        • California Maternal Quality Care Collaborative
        The California pregnancy-associated mortality review report: pregnancy- associated suicide, 2002-2012.
        (Available at:)
        • Schiff D.M.
        • Nielsen T.
        • Terplan M.
        • et al.
        Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts.
        Obstet Gynecol. 2018; 132: 466-474
        • Zaharatos J.
        • St Pierre A.
        • Cornell A.
        • Pasalic E.
        • Goodman D.
        Building U.S. capacity to review and prevent maternal deaths.
        J Womens Health (Larchmt). 2018; 27: 1-5
        • Hardt N.
        • Wong T.D.
        • Burt M.J.
        • Harrison R.
        • Winter W.
        • Roth J.
        Prevalence of prescription and illicit drugs in pregnancy-associated non-natural deaths of Florida mothers, 1999-2005.
        J Forensic Sci. 2013; 58: 1536-1541
        • Metz T.D.
        • Rovner P.
        • Hoffman M.C.
        • Allshouse A.A.
        • Beckwith K.M.
        • Binswanger I.A.
        Maternal deaths from suicide and overdose in Colorado, 2004-2012.
        Obstet Gynecol. 2016; 128: 1233-1240
        • Smid M.C.
        • Stone N.M.
        • Baksh L.
        • et al.
        Pregnancy-associated death in Utah: contribution of drug-induced deaths.
        Obstet Gynecol. 2019; 133: 1131-1140
        • Goldman-Mellor S.
        • Margerison C.E.
        Maternal drug-related death and suicide are leading causes of postpartum death in California.
        Am J Obstet Gynecol. 2019; 221: 489.e1-489.e9
        • Austin A.E.
        • Vladutiu C.J.
        • Jones-Vessey K.A.
        • Norwood T.S.
        • Proescholdbell S.K.
        • Menard M.K.
        Improved ascertainment of pregnancy-associated suicides and homicides in North Carolina.
        Am J Prev Med. 2016; 51: S234-S240
        • Platner M.
        • Loucks T.L.
        • Lindsay M.K.
        • Ellis J.E.
        Pregnancy-associated deaths in rural, nonrural, and metropolitan areas of Georgia.
        Obstet Gynecol. 2016; 128: 113-120
        • Mehta P.K.
        • Bachhuber M.A.
        • Hoffman R.
        • Srinivas S.K.
        Deaths from unintentional injury, homicide, and suicide during or within 1 year of pregnancy in Philadelphia.
        Am J Public Health. 2016; 106: 2208-2210
        • Maryland Department of Health
        Maryland Maternal Mortality Review 2018 Annual Report.
        (Available at:)
        • Virginia Department of Health Office of the Chief Medical Examiner
        Pregnancy-associated deaths from drug overdose in Virginia, 1999-2007. A report from the Virginia Maternal Mortality Review Team.
        (Available at:)
        • Wright T.E.
        • Terplan M.
        • Ondersma S.J.
        • et al.
        The role of screening, brief intervention, and referral to treatment in the perinatal period.
        Am J Obstet Gynecol. 2016; 215: 539-547
        • Ko J.Y.
        • Tong V.T.
        • Haight S.C.
        • et al.
        Obstetrician-gynecologists’ practices and attitudes on substance use screening during pregnancy.
        J Perinatol. 2020; 40: 422-432
        • Holland C.L.
        • Nkumsah M.A.
        • Morrison P.
        • et al.
        ”Anything above marijuana takes priority”: obstetric providers’ attitudes and counseling strategies regarding perinatal marijuana use.
        Patient Educ Couns. 2016; 99: 1446-1451
        • Saitz R.
        • Mulvey K.P.
        • Plough A.
        • Samet J.H.
        Physician unawareness of serious substance abuse.
        Am J Drug Alcohol Abuse. 1997; 23: 343-354
        • Ko J.Y.
        • Tong V.T.
        • Haight S.C.
        • Terplan M.
        • Snead C.
        • Schulkin J.
        Obstetrician-gynecologists’ practice patterns related to opioid use during pregnancy and postpartum–United States, 2017.
        J Perinatol. 2020; 40: 412-421
        • Madsen A.M.
        • Stark L.M.
        • Has P.
        • Emerson J.B.
        • Schulkin J.
        • Matteson K.A.
        Opioid knowledge and prescribing practices among obstetrician-gynecologists.
        Obstet Gynecol. 2018; 131: 150-157
        • Maryland Department of Health
        Maryland Maternal Mortality Review 2017 Annual Report.
        (Available at:)
        • Georgia Department of Health
        Maternal mortality.
        (Available at:)
        Date accessed: February 13, 2020
        • Centers for Disease Control and Prevention Foundation
        Building U.S. capacity to review and prevent maternal deaths.
        (Available at:)
        • Committee on Obstetric Practice
        Committee opinion no. 711: opioid use and opioid use disorder in pregnancy.
        Obstet Gynecol. 2017; 130: e81-e94
        • Humeniuk R.
        • Ali R.
        • Babor T.F.
        • et al.
        Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).
        Addiction. 2008; 103: 1039-1047
        • Ondersma S.J.
        • Svikis D.S.
        • LeBreton J.M.
        • et al.
        Development and preliminary validation of an indirect screener for drug use in the perinatal period.
        Addiction. 2012; 107: 2099-2106
        • Chasnoff I.J.
        • Wells A.M.
        • McGourty R.F.
        • Bailey L.K.
        Validation of the 4P’s Plus screen for substance use in pregnancy validation of the 4P’s Plus.
        J Perinatol. 2007; 27: 744-748
        • Chasnoff I.J.
        • McGourty R.F.
        • Bailey G.W.
        • et al.
        The 4P’s Plus screen for substance use in pregnancy: clinical application and outcomes.
        J Perinatol. 2005; 6: 368-374
        • Chang G.
        • Orav E.J.
        • Jones J.A.
        • Buynitsky T.
        • Gonzalez S.
        • Wilkins-Haug L.
        Self-reported alcohol and drug use in pregnant young women: a pilot study of associated factors and identification.
        J Addict Med. 2011; 5: 221-226
        • Coleman-Cowger V.H.
        • Oga E.A.
        • Peters E.N.
        • Trocin K.E.
        • Koszowski B.
        • Mark K.
        Accuracy of three screening tools for prenatal substance use.
        Obstet Gynecol. 2019; 133: 952-961
        • Finer L.B.
        • Zolna M.R.
        Declines in unintended pregnancy in the United States, 2008-2011.
        N Engl J Med. 2016; 374: 843-852
        • Miller W.
        • Forcehimes A.
        • Zweben A.
        Treating addiction: a guide for professionals.
        Guilford Press, New York2011
        • Roberts S.C.
        • Nuru-Jeter A.
        Women’s perspectives on screening for alcohol and drug use in prenatal care.
        Womens Health Issues. 2010; 20: 193-200
        • Roberts S.C.
        • Nuru-Jeter A.
        Universal screening for alcohol and drug use and racial disparities in child protective services reporting.
        J Behav Health Serv Res. 2012; 39: 3-16
        • Boudreaux J.M.
        • Thompson Jr., J.W.
        Maternal-fetal rights and substance abuse: gestation without representation.
        J Am Acad Psychiatry Law. 2015; 43: 137-140
        • Polak K.
        • Kelpin S.
        • Terplan M.
        Screening for substance use in pregnancy and the newborn.
        Semin Fetal Neonat Med. 2019; 24: 90-94
        • Kroelinger C.D.
        • Rice M.E.
        • Cox S.
        • et al.
        State strategies to address opioid use disorder among pregnant and postpartum women and infants prenatally exposed to substances, including infants with neonatal abstinence syndrome.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 777-783
        • Isaacson J.H.
        • Fleming M.
        • Kraus M.
        • Kahn R.
        • Mundt M.
        A national survey of training in substance use disorders in residency programs.
        J Stud Alcohol. 2000; 61: 912-915
        • Garbarino A.H.
        • Kohn J.R.
        • Coverdale J.H.
        • Kilpatrick C.C.
        Current trends in psychiatric education among obstetrics and gynecology residency programs.
        Acad Psychiatry. 2019; 43: 294-299
        • Jones H.E.
        • Deppen K.
        • Hudak M.L.
        • et al.
        Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.
        Am J Obstet Gynecol. 2014; 210: 302-310
        • Hollander M.A.G.
        • Jarlenski M.P.
        • Donohue J.M.
        • Cole E.S.
        • Kelley D.
        • Krans E.E.
        Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
        Am J Obstet Gynecol. 2019; 220: 502-503
        • Short V.L.
        • Hand D.J.
        • MacAfee L.
        • Abatemarco D.J.
        • Terplan M.
        Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.
        J Subst Abuse Treat. 2018; 89: 67-74
        • Patrick S.W.
        • Buntin M.B.
        • Martin P.R.
        • et al.
        Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
        Subst Abus. 2019; 40: 356-362
        • Bastian J.R.
        • Chen H.
        • Zhang H.
        • et al.
        Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
        Am J Obstet Gynecol. 2017; 216: 64.e1-64.e7
        • Caritis S.N.
        • Bastian J.R.
        • Zhang H.
        • et al.
        An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.
        Am J Obstet Gynecol. 2017; 217: 459.e1-459.e6
        • Zhang H.
        • Kalluri H.V.
        • Bastian J.R.
        • et al.
        Gestational changes in buprenorphine exposure: a physiologically-based pharmacokinetic analysis.
        Br J Clin Pharmacol. 2018; 84: 2075-2087
        • Drozdick 3rd, J.
        • Berghella V.
        • Hill M.
        • Kaltenbach K.
        Methadone trough levels in pregnancy.
        Am J Obstet Gynecol. 2002; 187: 1184-1188
        • Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment
        Substance abuse treatment: addressing the specific needs of women. Treatment improvement protocol (TIP) series, No. 51.
        Substance Abuse and Mental Health Services Administration, Rockville, MD2009
        • O’Connor P.G.
        • Sokol R.J.
        • D’Onofrio G.
        Addiction medicine: the birth of a new discipline.
        JAMA Intern Med. 2014; 174: 1717-1718
        • World Health Organization
        Guidelines for the identification and management of substance use and substance use disorders in pregnancy.
        (Available at:)
        • Howard H.
        • Clark K.
        Interprofessional-shared decision making for pregnant women with opioid use: results from a provider training.
        Curr Womens Health Rev. 2017; 13: 121-129
        • Krans E.E.
        • Campopiano M.
        • Cleveland L.M.
        • et al.
        National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder.
        Obstet Gynecol. 2019; 134: 365-375
        • Brooks K.
        America is blaming pregnant women for their own deaths.
        The New York Times, 2018 (Available at:)
        • Goldensohn R.
        They shared drugs. Someone died. Does that make them killers? The New York Times.
        (Available at:)
        • McGreal C.
        ‘I don’t want to overdose and die:’ one woman’s death, one country’s shame.
        The Guardian, 2020 (Available at:) (Accessed February 13, 2020)
        • Faherty L.J.
        • Kranz A.M.
        • Russell-Fritch J.
        • Patrick S.W.
        • Cantor J.
        • Stein B.D.
        Association of punitive and reporting state policies related to substance use in pregnancy with rates of neonatal abstinence syndrome.
        JAMA Netw Open. 2019; 2: e1914078
        • Nielsen T.
        • Bernson D.
        • Terplan M.
        • et al.
        Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
        Addiction. 2020; 115: 291-301
        • Zelenko M.
        • Lock J.
        • Kraemer H.C.
        • Steiner H.
        Perinatal complications and child abuse in a poverty sample.
        Child Abuse Negl. 2000; 24: 939-950
        • Tsantefski M.
        • Humphreys C.
        • Jackson A.C.
        Infant risk and safety in the context of maternal substance use.
        Child Youth Serv Rev. 2014; 47: 10-17
        • Beardon P.H.
        • McGilchrist M.M.
        • McKendrick A.D.
        • McDevitt D.G.
        • MacDonald T.M.
        Primary non-compliance with prescribed medication in primary care.
        BMJ. 1993; 307: 846-848
        • Spelke B.
        • Ramos S.
        • Yu H.
        • Cohen M.
        • Booker T.L.
        On the future of maternal mortality review in Rhode Island.
        R I Med J (2013). 2018; 101: 34-36
        • Hulsey E.G.
        • Li Y.
        • Hacker K.
        • Williams K.
        • Collins K.
        • Dalton E.
        Potential emerging risks among children following parental opioid-related overdose death.
        JAMA Pediatr. 2020; 174: 503-504
        • Kramer M.R.
        • Strahan A.E.
        • Preslar J.
        • et al.
        Changing the conversation: applying a health equity framework to maternal mortality reviews.
        Am J Obstet Gynecol. 2019; 221: 609.e1-609.e9
        • Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion
        Rapid assessment of maternal opioid use and overdose.
        (Available at:)
        • Wilder C.
        • Lewis D.
        • Winhusen T.
        Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
        Drug Alcohol Depend. 2015; 149: 225-231
        • Fischer G.
        • Eder H.
        • Jagsch R.
        • et al.
        Maintenance therapy with synthetic opioids within a multidisciplinary program - a stabilizing necessity for pregnant opioid dependent women.
        Arch Womens Ment Health. 1998; 1: 109-116
        • Clark H.W.
        Residential substance abuse treatment for pregnant and postpartum women and their children: treatment and policy implications.
        Child Welfare. 2001; 80: 179-198
        • Schauberger C.W.
        • Borgert A.J.
        • Bearwald B.
        Continuation in treatment and maintenance of custody of newborns after delivery in women with opioid use disorder.
        J Addict Med. 2020; 14: 119-125
        • Mattocks K.M.
        • Clark R.
        • Weinreb L.
        Initiation and engagement with methadone treatment among pregnant and postpartum women.
        Womens Health Issues. 2017; 27: 646-651
        • Kelly P.J.
        • Blacksin B.
        • Mason E.
        Factors affecting substance abuse treatment completion for women.
        Issues Ment Health Nurs. 2001; 22: 287-304
        • American College of Obstetricians and Gynecologists
        ACOG committee opinion no. 736: optimizing postpartum care.
        Obstet Gynecol. 2018; 131: e140-e150
        • Gordon S.H.
        • Sommers B.D.
        • Wilson I.B.
        • Trivedi A.N.
        Effects of Medicaid expansion on postpartum coverage and outpatient utilization.
        Health Aff (Millwood). 2020; 39: 77-84
        • Normile B.
        • Hanlon C.
        • Eichner H.
        State options for promoting recovery among pregnant and parenting women with opioid or substance use disorder.
        (Available at:)